

# ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT03922555

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Massachusetts General Hospital
Enrollment	18 participants

## Key Eligibility Criteria

---

### Inclusion (25)

- Participants must be ≥18 years of age.
- Participants must have histologically or cytologically confirmed glioma, with documented IDH1 and/or IDH2 gene-mutation.
- Participants must have radiographic evidence of non-enhancing disease progression/recurrence per RANO criteria for low grade gliomas (LGG).
- Patients who have received prior treatment with chemotherapy, radiation, or a combination of both are eligible. Also, patients who have not received any prior treatment for their glioma are also eligible.
- Participants must be ≥12 weeks from completion of radiation.

... and 20 more (see full listing online)

### Exclusion (16)

- Participants with enhancing disease on brain MRI.
- Participants who received systemic anticancer therapy <28 days prior to registration. One exception: participants on lomustine/CCNU must wait at least 42 days from last date of drug administration to registration.
- Participants who received an investigational agent <14 days prior to registration. In addition, the first dose of ASTX727 should not occur before a period ≥5 half-lives of the investigational agent has elapsed.
- Participants with prior treatment with bevacizumab (Avastin) are excluded.
- Participants who are pregnant or breast-feeding.

... and 11 more (see full listing online)

## Locations (3 total)

---

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States  
Brigham and Women's Hospital, Boston, Massachusetts, United States  
Dana Farber Cancer Institute, Boston, Massachusetts, United States